As of 2024-07-27, the Relative Valuation of Harvard Bioscience Inc (HBIO) is (6.37) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.30 USD, the upside of Harvard Bioscience Inc based on Relative Valuation is -293.0%.
The range of the Relative Valuation is (6.10) - (6.84) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 30.3x - 34.7x | 31.8x |
| Forward P/E multiples | 28.6x - 34.0x | 31.6x |
| Fair Price | (6.10) - (6.84) | (6.37) |
| Upside | -284.9% - -307.3% | -293.0% |
| Date | P/E |
| 2024-07-26 | -16.41 |
| 2024-07-25 | -16.66 |
| 2024-07-24 | -16.16 |
| 2024-07-23 | -16.41 |
| 2024-07-22 | -15.57 |
| 2024-07-19 | -15.32 |
| 2024-07-18 | -15.82 |
| 2024-07-17 | -17.21 |
| 2024-07-16 | -17.61 |
| 2024-07-15 | -16.51 |
| 2024-07-12 | -16.21 |
| 2024-07-11 | -16.31 |
| 2024-07-10 | -14.32 |
| 2024-07-09 | -13.83 |
| 2024-07-08 | -13.85 |
| 2024-07-05 | -13.53 |
| 2024-07-03 | -13.78 |
| 2024-07-02 | -13.88 |
| 2024-07-01 | -13.83 |
| 2024-06-28 | -14.17 |
| 2024-06-27 | -14.42 |
| 2024-06-26 | -14.37 |
| 2024-06-25 | -14.47 |
| 2024-06-24 | -14.17 |
| 2024-06-21 | -14.03 |
| 2024-06-20 | -14.27 |
| 2024-06-18 | -14.62 |
| 2024-06-17 | -14.52 |
| 2024-06-14 | -14.40 |
| 2024-06-13 | -14.47 |
| 2024-06-12 | -14.82 |
| 2024-06-11 | -13.78 |
| 2024-06-10 | -13.93 |
| 2024-06-07 | -14.62 |
| 2024-06-06 | -14.82 |
| 2024-06-05 | -15.27 |
| 2024-06-04 | -15.57 |
| 2024-06-03 | -15.82 |
| 2024-05-31 | -15.77 |
| 2024-05-30 | -15.52 |
| 2024-05-29 | -15.42 |
| 2024-05-28 | -15.82 |
| 2024-05-24 | -15.72 |
| 2024-05-23 | -15.82 |
| 2024-05-22 | -16.41 |
| 2024-05-21 | -16.26 |
| 2024-05-20 | -16.26 |
| 2024-05-17 | -16.76 |
| 2024-05-16 | -17.11 |
| 2024-05-15 | -17.16 |